Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 (original) (raw)
Korsmeyer, S.J. Chromosomal translations in lymphoid malignancies reveal novel proto-oncogenes. Annu. Rev. Immunol.10, 785–607 (1992). ArticleCASPubMed Google Scholar
Taniwaki, M. et al. Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood84, 2283–2290 (1994). CASPubMed Google Scholar
Sawyer, J.R., Waldron, J.A., Jagannath, S. & Barlogie, B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet. Cytogenet.82, 41–49 (1995). ArticleCASPubMed Google Scholar
Lai, J.L. et al. Improved cytogenetics in multiple-myeloma—a study of 151 patients including 117 patients at diagnosis. Blood85, 2490–2497 (1995). CASPubMed Google Scholar
Chesi, M. et al. Dysregulation of Cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood88, 674–681 (1996). CASPubMed Google Scholar
Bergsagel, P.L. et al. Promiscuous translations into IgH switch regions in multiple myeloma. Proc. Natl. Sci. Acad. USA93, 13931–13936 (1996). ArticleCAS Google Scholar
Baxendale, S. et al. A cosmid contig and high resolution restriction map of the 2 megabase region containing the Huntington's disease gene. Nature Genet.4, 181–186 (1993). ArticleCASPubMed Google Scholar
Keegan, K., Johnson, D., William, L.T. & Hayman, M.J. Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc. Natl. Acad Sci. USA88, 1095–1099(1991). ArticleCASPubMedPubMed Central Google Scholar
Keegan, K., Meyer, S. & Hayman, M.J. Structural and biosynthetic characterization of the fibroblast growth factor receptor 3 (FGFR-3) protein. Oncogene6, 2229–2236 (1991). CASPubMed Google Scholar
Muenke, M. & Schell, U. Fibroblast-growth-factor-receptor mutations in human sketetal disorders. Trends Genet.11, 308–313 (1995). ArticleCASPubMed Google Scholar
Naski, M.C., Wang, Q., Xu, J. & Ornitz, D.M. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nature Genet.13, 233–237 (1996). ArticleCASPubMed Google Scholar
Webster, M.K., D'Avis, P.Y., Robertson, S.C. & Donoghue, D.J. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol. Cell. Biol.16, 4081–4087 (1996). ArticleCASPubMedPubMed Central Google Scholar
Webster, M.K. & Donoghue, D.J. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J.15, 520–527 (1996). ArticleCASPubMedPubMed Central Google Scholar
Rousseau, F. et al. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism typeI (TD1). Hum. Mol. Genet.5, 509–512 (1996). ArticleCASPubMed Google Scholar
Francomano, C.A. et al. A new skeletal dysplasia with severe tibial bowing, profound developmental delay and acanthosis nigricans is caused by a Lys 650 Met mutation in fibroblast growth factor receptor 3 (FGFR3). Am. J. Hum. Genet.59, A25 (1996). Google Scholar
Tavormina, P.L. et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nature Genet.9, 321–328 (1995). ArticleCASPubMed Google Scholar
Williams, M.E., Swerdlow, S.H. & Meeker, T.C. Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster. Leukemia7, 1437–1440 (1993). CASPubMed Google Scholar
Tsujimoto, Y. et al. Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature315, 340–343 (1985). ArticleCASPubMed Google Scholar
de Boer, C.J. et al. Multiple breakpoints within the BCL-1 locus in B-cell lymphoma: rearrangements of the cyclin D1 gene. Cancer Res.53, 4148–4152 (1993). CASPubMed Google Scholar
Su, W.S. et al. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature386, 288–292 (1997). ArticleCASPubMed Google Scholar
Colvin, J.S., Bohne, B.A., Harding, G.W., McEwen, D.G. & Ornitz, D.M. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nature Genet.12, 390–397 (1996). ArticleCASPubMed Google Scholar
Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A. & Leder, P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell84, 911–921 (1996). ArticleCASPubMed Google Scholar
Ornitz, D.M. & Leder, P. Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3. J. Biol. Chem.267, 16305–16311 (1992). CASPubMed Google Scholar
Caligaris-Cappio, F. et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood77, 2688–2693 (1991). CASPubMed Google Scholar
Allouche, M. Basic fibroblast growth factor and hematopoiesis. Leukemia9, 937–942 (1995). CASPubMed Google Scholar
Shiang, R. et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell78, 335–342 (1994). ArticleCASPubMed Google Scholar
Johnston, C.L., Cox, H.C., Gomm, J.J. & Coombes, R.C. Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. J. Biol. Chem.270, 30643–30650 (1995). ArticleCASPubMed Google Scholar
Schröck, E. et al. Multicolor spectral karyotyping of human chromosomes. Science273, 494–497 (1996). ArticlePubMed Google Scholar
Kuehl, W.M., Brents, L.A., Chesi, M. & Bergsagel, P.L. Selective expression of one c-myc allele in two human myeloma cell lines. Cancer Res.56, 4370–4373 (1996). CASPubMed Google Scholar
Davis, L.G., Kuehl, W.M. & Battey, J.F., Methods in Molecular Biology (Appleton & Lange, Norwalk, Connecticut, 1994). Google Scholar